Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266058 | 0.98 | CYP1A2 (0.31) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28375754 | 0.79 | CYP1A2 (0.34) | CYP1A2CYP2D6 | |
| SCHEMBL21815441 | 0.78 | CYP1A2 (0.31) | CYP1A2CYP2D6 | |
| SCHEMBL531924 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL2289852 | 0.74 | — | — | |
| SCHEMBL19915260 | 0.73 | CYP1A2 (0.31) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL2237708 | 0.73 | CYP1A2 (0.31) | CYP1A2CYP2D6 | |
| SCHEMBL4429221 | 0.73 | — | — | |
| SCHEMBL8159853 | 0.71 | CYP1A2 (0.30) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL2997324 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115852521-A | Environment-friendly wig and preparation method thereof | 邵阳深镁科技时尚有限公司 | 2023-03-28 | — | — | CN | claimed |
| US-11802108-B2 | Compounds for the modulation of cyclophilins function | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2023-10-31 | — | — | US | disclosed |
| WO-2023108291-A9 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023108291-A1 | APELINERGIC MACROCYCLES AND USES THEREOF | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-06-22 | — | — | WO | disclosed |
| US-20230183282-A1 | REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-06-15 | — | — | US | disclosed |
| CN-115852521-A | Environment-friendly wig and preparation method thereof | 邵阳深镁科技时尚有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115715190-A | Redeciclovir and Redeciclovir analogs, solutions and nanoparticle, liposome and microparticle compositions for treating viral infections | 密歇根大学董事会 | 2023-02-24 | — | — | CN | disclosed |
| WO-2021202907-A2 | REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210238130-A1 | COMPOUNDS FOR THE MODULATION OF CYCLOPHILINS FUNCTION | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3843841-A1 | COMPOUNDS FOR THE MODULATION OF CYCLOPHILINS FUNCTION | The University Court Of The University of Edinburgh (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-6407111-B1 | SUBSTANCE P OR NEUROKININ 1 ANTAGONISTS; ANTIINFLAMMATORY, ANTIDEPRESSANT, ANTIARTHRITIC, AND ANTIASTHMATIC AGENTS; PARKINSON*S DISEASE, INFLAMMATORY BOWEL DISEASE, CENTRAL NERVOUS SYSTEM AND RHEUMATIC DISORDERS | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2000035860-A2 | ACYL ISOTHIOCYANATE RESINS AND THEIR USE IN SOLID-SUPPORTED SYNTHESIS OF GUANIDINES | THE PROCTER & GAMBLE COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| US-5827846-A | Carbazole derivatives as agents against multi-drug resistance | NOVARTIS CORP. (US) | 1998-10-27 | — | — | US | disclosed |
| EP-0763042-A1 | POLYCYCLIC LACTAM DERIVATIVES FOR SENSITIZING MULTIDRUG-RESISTANT CELLS TO ANTITUMOUR AGENTS | Novartis AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| EP-0763040-A1 | CARBAZOLE DERIVATIVES AS AGENTS AGAINST MULTI-DRUG RESISTANCE | Novartis AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| US-5610140-A | ANALGESICS, ANTIINFLAMMTORY AGENTS; TREATMENT OF ASTHMA | CORTECH, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1995032976-A1 | POLYCYCLIC LACTAM DERIVATIVES FOR SENSITIZING MULTIDRUG-RESISTANT CELLS TO ANTITUMOUR AGENTS | CIBA-GEIGY AG (CH) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995032974-A1 | CARBAZOLE DERIVATIVES AS AGENTS AGAINST MULTI-DRUG RESISTANCE | CIBA-GEIGY AG (CH) | 1995-12-07 | — | — | WO | disclosed |
| US-4954512-A | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1990-09-04 | — | — | US | disclosed |
| EP-0317959-A2 | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802108-B2 | Compounds for the modulation of cyclophilins function | CBR1, CBR3, PPIC | CYP1A2 1266/4885CYP2D6 1200/4885 |
| US-20210238130-A1 | COMPOUNDS FOR THE MODULATION OF CYCLOPHILINS FUNCTION | CBR1, CBR3, PPIC | CYP1A2 1266/4885CYP2D6 1200/4885 |
| US-20230183282-A1 | REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS | ALB, ACE, ACE2 | CYP1A2 743/4885CYP2D6 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.